Moderna (MRNA) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Moderna Reports First Quarter 2020 Financial Results and Provides Business Updates
May 7, 2020 7:00 AM EDTProgress on novel coronavirus vaccine (mRNA-1273) includes FDA clearance to proceed with Phase 2 study
Finalizing protocol for Phase 3 study of mRNA-1273, expected to begin in early summer of 2020
Awarded up to $483 million funding from BARDA for accelerated development of mRNA-1273
Entered strategic collaboration with Lonza Ltd. to manufacture up to one billion doses of mRNA-1273 per year
Up to $2.4 billion to invest, including cash and investments of $1.7 billion and up to $0.7 billion in potentially available grants and awards; reconfirms... More
